Tune into this episode of Covington’s Life Sciences Audiocast, where Winsome Cheung and George Jenkins discuss the key trends in Life Sciences Transactions for 2024. The speakers discuss the outlook for deal-making in Life Sciences and predictions for deal trends, including in relation to nuclear medicine, GLP-1, antibody-drug conjugates and other modalities. The speakers also discuss some of the key legal considerations that are coming into increasing focus for Life Sciences Transactions, such as competition/antitrust considerations and the Inflation Reduction Act. This is the first Life Sciences Transactions audiocast for 2024, and we plan to release further audiocasts over the course of this year that dive deeper into some of the above topics.

Photo of Winsome Cheung Winsome Cheung

Winsome Cheung assists life sciences and technology companies to develop and commercialise their intellectual property assets. She advises on their strategic licensing and partnering transactions, and intellectual property and commercial matters throughout the entire product lifecycle.
Winsome Cheung is a partner in Covington’s…

Winsome Cheung assists life sciences and technology companies to develop and commercialise their intellectual property assets. She advises on their strategic licensing and partnering transactions, and intellectual property and commercial matters throughout the entire product lifecycle.
Winsome Cheung is a partner in Covington’s life science transactions team.

She advises a broad range of clients in the life sciences and technology industries, from start-ups, venture capital investors to global pharmaceutical companies. As a former scientist, she combines her scientific understanding with her legal and commercial knowledge to help companies build value and monetise their intellectual property assets.

Winsome regularly advises on:

  • Complex partnering arrangements, including licensing, collaboration, co-development, co-promotion and other strategic arrangements.
  • Commercial agreements throughout the entire lifecycle of life sciences and technology assets, including CRO, clinical trial, manufacturing and distribution agreements.
  • Intellectual property and commercial matters in relation to corporate transactions and venture investments, including:
    • IP and commercial diligence;
    • Ancillary/transitional agreements; and
    • IP warranties, contingent consideration provisions of share purchase/asset purchase agreements.

Prior to her legal career, Winsome completed an undergraduate degree in Biochemistry and a PhD in Medicine. During her doctoral research, she discovered a novel virus-host cell interaction which led to major scientific publications, and explored commercialisation of this research.

Photo of George Jenkins George Jenkins

George Jenkins sits in Covington’s Band 1 ranked Life Sciences Transactions team, specializing in advising life sciences and digital health clients on complex, strategic commercial agreements. In particular, he advises clients on structuring, negotiating and drafting their collaborations, joint ventures, IP licensing, co-development…

George Jenkins sits in Covington’s Band 1 ranked Life Sciences Transactions team, specializing in advising life sciences and digital health clients on complex, strategic commercial agreements. In particular, he advises clients on structuring, negotiating and drafting their collaborations, joint ventures, IP licensing, co-development arrangements, and agreements for the manufacture, distribution, and supply of goods. George also regularly works closely with the firm’s Corporate Practice Group on product divestments, asset transfers, and related transitional agreements.

George has experience in advising on regulatory matters in the life sciences sector, including advising on regulatory and licensing requirements to enable clients to develop and commercialize their products in the EU. He understands the regulatory environment affecting the life sciences industry and is able to assist clients in setting their commercial arrangements and transactions in their wider regulatory context.

George has also spent time in the in-house legal teams of a number of clients, including at the headquarters of a global pharmaceutical company.